FDA Clearance Tracker · K260468
H100Plus Hemoglobin Testing System
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Oct 2, 2026
Substantially Equivalent
Time to decision
232 days
Received Feb 12, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K260468
- Device name
- H100Plus Hemoglobin Testing System
- Applicant location
- Shenzhen, CN
- Received
- Feb 12, 2026
- Decided
- Oct 2, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Hemoglobin A1c Test System (PDJ)
- Device class
- Class II
- Regulation
- 21 CFR 862.1373
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PDJ. The earliest in FDA's data is DEN130002, decided May 23, 2013.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K260468
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Shenzhen Lifotronic Technology Co., Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K251076 · Decided Jul 30, 2025 · 113 days after receipt
Device type: Powered Laser Surgical Instrument (GEX) · General & Plastic Surgery
K192466 · Decided Jun 22, 2020 · 287 days after receipt
Device type: Massager, Powered Inflatable Tube (IRP) · Physical Medicine & Rehabilitation
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.